系统免疫炎症指数在呼吸系统肿瘤中的研究进展
Research Advances in the Systemic Immune-Inflammation Index in Respiratory System Tumors
DOI: 10.12677/wjcr.2026.164029, PDF,   
作者: 王 蕊：济宁医学院临床医学院，山东 济宁；韩丽萍*：济宁市第一人民医院呼吸与危重症医学科，山东 济宁
关键词: 系统免疫炎症指数；呼吸系统肿瘤；肺癌；非小细胞肺癌；小细胞肺癌；预后；免疫治疗；Systemic Immune-Inflammation Index (SII)； Respiratory System Tumors； Lung Cancer； Non-Small Cell Lung Cancer； Small Cell Lung Cancer； Prognosis； Immunotherapy
摘要: 系统免疫炎症指数(systemic immune-inflammation index, SII)是以外周血中性粒细胞、血小板与淋巴细胞计数为基础构建的复合炎症指标，能够综合反映宿主的系统性炎症状态与抗肿瘤免疫功能的失衡。近年来越来越多的证据表明，治疗前高SII与呼吸系统恶性肿瘤(尤其是非小细胞肺癌与小细胞肺癌)的不良预后密切相关。本文在系统检索文献的基础上，从SII的生物学基础、在肺癌各期中的预后价值、免疫治疗中的预测价值及特殊人群中的应用等方面，对SII在呼吸系统肿瘤中的研究进展作一综述。总体而言，SII作为一种低成本、简便、无创且易获取的预后标志物，在呼吸系统肿瘤的风险分层与个体化治疗决策中展现出良好前景，有望成为呼吸系统肿瘤个体化治疗决策中实用的生物标志物。
Abstract: The systemic immune-inflammation index (SII) is a composite inflammatory indicator derived from peripheral blood neutrophil, platelet, and lymphocyte counts, which comprehensively reflects the host’s systemic inflammatory status and the imbalance between systemic inflammation and antitumor immune function. In recent years, accumulating evidence has indicated that a high pretreatment SII is closely associated with poor prognosis in respiratory system malignancies, particularly non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Based on a systematic literature search, this review summarizes recent advances in the research of SII in respiratory system tumors, focusing on its biological basis, prognostic value across different stages of lung cancer, predictive value in immunotherapy, and application in special populations. Overall, as a low-cost, simple, non-invasive, and readily accessible prognostic marker, SII shows promising prospects for risk stratification and individualized treatment decision-making in respiratory system tumors, and is expected to become a practical biomarker for guiding individualized therapy.
文章引用：王蕊, 韩丽萍. 系统免疫炎症指数在呼吸系统肿瘤中的研究进展[J]. 世界肿瘤研究, 2026, 16(4): 276-282. https://doi.org/10.12677/wjcr.2026.164029

参考文献

[1] Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 74, 229-263.
https://doi.org/10.3322/caac.21834
[2] Reck, M. and Rabe, K.F. (2017) Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. New England Journal of Medicine, 377, 849-861.
https://doi.org/10.1056/nejmra1703413
[3] Balkwill, F. and Mantovani, A. (2001) Inflammation and Cancer: Back to Virchow? The Lancet, 357, 539-545.
https://doi.org/10.1016/s0140-6736(00)04046-0
[4] Candido, J. and Hagemann, T. (2013) Cancer-Related Inflammation. Journal of Clinical Immunology, 33, 79-84.
https://doi.org/10.1007/s10875-012-9847-0
[5] Hu, B., Yang, X., Xu, Y., Sun, Y., Sun, C., Guo, W., et al. (2014) Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma. Clinical Cancer Research, 20, 6212-6222.
https://doi.org/10.1158/1078-0432.ccr-14-0442
[6] Zhong, J.H., Huang, D.H. and Chen, Z.Y. (2017) Prognostic Role of Systemic Immune-Inflammation Index in Solid Tumors: A Systematic Review and Meta-Analysis. Oncotarget, 8, 75381-75388.
https://doi.org/10.18632/oncotarget.18856
[7] Yang, R., Chang, Q., Meng, X., Gao, N. and Wang, W. (2018) Prognostic Value of Systemic Immune-Inflammation Index in Cancer: A Meta-Analysis. Journal of Cancer, 9, 3295-3302.
https://doi.org/10.7150/jca.25691
[8] Burn, G.L., Foti, A., Marsman, G., Patel, D.F. and Zychlinsky, A. (2021) The Neutrophil. Immunity, 54, 1377-1391.
https://doi.org/10.1016/j.immuni.2021.06.006
[9] Hedrick, C.C. and Malanchi, I. (2022) Neutrophils in Cancer: Heterogeneous and Multifaceted. Nature Reviews Immunology, 22, 173-187.
https://doi.org/10.1038/s41577-021-00571-6
[10] Giese, M.A., Hind, L.E. and Huttenlocher, A. (2019) Neutrophil Plasticity in the Tumor Microenvironment. Blood, 133, 2159-2167.
https://doi.org/10.1182/blood-2018-11-844548
[11] Repsold, L. and Joubert, A.M. (2021) Platelet Function, Role in Thrombosis, Inflammation, and Consequences in Chronic Myeloproliferative Disorders. Cells, 10, Article No. 3034.
https://doi.org/10.3390/cells10113034
[12] Mitrugno, A., Tormoen, G.W., Kuhn, P. and McCarty, O.J.T. (2016) The Prothrombotic Activity of Cancer Cells in the Circulation. Blood Reviews, 30, 11-19.
https://doi.org/10.1016/j.blre.2015.07.001
[13] 彭千宇. 血小板通过上调PD-L1促非小细胞肺癌免疫逃逸作用机制[D]: [硕士学位论文]. 杭州: 浙江省医学科学院, 2024.
[14] Chaplin, D.D. (2010) Overview of the Immune Response. Journal of Allergy and Clinical Immunology, 125, S3-S23.
https://doi.org/10.1016/j.jaci.2009.12.980
[15] Schreiber, R.D., Old, L.J. and Smyth, M.J. (2011) Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion. Science, 331, 1565-1570.
https://doi.org/10.1126/science.1203486
[16] Zhao, J., Huang, W., Wu, Y., Luo, Y., Wu, B., Cheng, J., et al. (2020) Prognostic Role of Pretreatment Blood Lymphocyte Count in Patients with Solid Tumors: A Systematic Review and Meta-Analysis. Cancer Cell International, 20, Article No. 15.
https://doi.org/10.1186/s12935-020-1094-5
[17] Yang, J., Liu, Z. and Zhang, M. (2026) Association of Systemic Immune-Inflammation Index with All-Cause Mortality in Lung Cancer Patients Undergoing Radiotherapy: A Retrospective Cohort Study. Frontiers in Oncology, 16, Article ID: 1806392.
https://doi.org/10.3389/fonc.2026.1806392
[18] Tomita, M., Ayabe, T., Maeda, R. and Nakamura, K. (2018) Systemic Immune-Inflammation Index Predicts Survival of Patients after Curative Resection for Non-Small Cell Lung Cancer. In Vivo, 32, 663-667.
[19] Gao, Y., Zhang, H., Li, Y., Wang, D., Ma, Y. and Chen, Q. (2018) Preoperative Increased Systemic Immune-Inflammation Index Predicts Poor Prognosis in Patients with Operable Non-Small Cell Lung Cancer. Clinica Chimica Acta, 484, 272-277.
https://doi.org/10.1016/j.cca.2018.05.059
[20] Guo, W., Cai, S., Zhang, F., Shao, F., Zhang, G., Zhou, Y., et al. (2019) Systemic Immune‐Inflammation Index (SII) Is Useful to Predict Survival Outcomes in Patients with Surgically Resected Non‐small Cell Lung Cancer. Thoracic Cancer, 10, 761-768.
https://doi.org/10.1111/1759-7714.12995
[21] Fu, F., Deng, C., Wen, Z., Gao, Z., Zhao, Y., Han, H., et al. (2021) Systemic Immune-Inflammation Index Is a Stage-Dependent Prognostic Factor in Patients with Operable Non-Small Cell Lung Cancer. Translational Lung Cancer Research, 10, 3144-3154.
https://doi.org/10.21037/tlcr-21-267
[22] Tong, Y.S., Tan, J., Zhou, X., Song, Y. and Song, Y. (2017) Systemic Immune-Inflammation Index Predicting Chemoradiation Resistance and Poor Outcome in Patients with Stage III Non-Small Cell Lung Cancer. Journal of Translational Medicine, 15, Article No. 221.
https://doi.org/10.1186/s12967-017-1326-1
[23] Guo, D., Zhang, J., Jing, W., Liu, J., Zhu, H., Fu, L., et al. (2018) Prognostic Value of Systemic Immune-Inflammation Index in Patients with Advanced Non-Small-Cell Lung Cancer. Future Oncology, 14, 2643-2650.
https://doi.org/10.2217/fon-2018-0285
[24] Berardi, R., Santoni, M., Rinaldi, S., Bower, M., Tiberi, M., Morgese, F., et al. (2019) Pre-Treatment Systemic Immune-Inflammation Represents a Prognostic Factor in Patients with Advanced Non-Small Cell Lung Cancer. Annals of Translational Medicine, 7, Article No. 572.
https://doi.org/10.21037/atm.2019.09.18
[25] Hong, X., Cui, B., Wang, M., Yang, Z., Wang, L. and Xu, Q. (2015) Systemic Immune-Inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer. The Tohoku Journal of Experimental Medicine, 236, 297-304.
https://doi.org/10.1620/tjem.236.297
[26] Wang, D., Guo, D., Shi, F., Zhu, Y., Li, A., Kong, L., et al. (2019) The Predictive Effect of the Systemic Immune-Inflammation Index for Patients with Small-Cell Lung Cancer. Future Oncology, 15, 3367-3379.
https://doi.org/10.2217/fon-2019-0288
[27] Wang, C., Jin, S., Xu, S. and Cao, S. (2020) High Systemic Immune-Inflammation Index (SII) Represents an Unfavorable Prognostic Factor for Small Cell Lung Cancer Treated with Etoposide and Platinum-Based Chemotherapy. Lung, 198, 405-414.
https://doi.org/10.1007/s00408-020-00333-6
[28] Zhou, Y., Dai, M. and Zhang, Z. (2022) Prognostic Significance of the Systemic Immune-Inflammation Index (SII) in Patients with Small Cell Lung Cancer: A Meta-Analysis. Frontiers in Oncology, 12, Article ID: 814727.
https://doi.org/10.3389/fonc.2022.814727
[29] Yang, Y., Li, J., Wang, Y., Luo, L., Yao, Y. and Xie, X. (2024) Prognostic Value of the Systemic Immune-Inflammation Index in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Meta-Analysis. PLOS ONE, 19, e0312605.
https://doi.org/10.1371/journal.pone.0312605
[30] Zhang, Y., Chen, Y., Guo, C., Li, S. and Huang, C. (2025) Systemic Immune-Inflammation Index as a Predictor of Survival in Non-Small Cell Lung Cancer Patients Undergoing Immune Checkpoint Inhibition: A Systematic Review and Meta-Analysis. Critical Reviews in Oncology/Hematology, 210, Article ID: 104669.
https://doi.org/10.1016/j.critrevonc.2025.104669
[31] Li, C., Wu, J., Jiang, L., Zhang, L., Huang, J., Tian, Y., et al. (2023) The Predictive Value of Inflammatory Biomarkers for Major Pathological Response in Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemoimmunotherapy and Its Association with the Immune-Related Tumor Microenvironment: A Multi-Center Study. Cancer Immunology, Immunotherapy, 72, 783-794.
https://doi.org/10.1007/s00262-022-03262-w
[32] Huai, Q., Luo, C., Song, P., Bie, F., Bai, G., Li, Y., et al. (2023) Peripheral Blood Inflammatory Biomarkers Dynamics Reflect Treatment Response and Predict Prognosis in Non‐small Cell Lung Cancer Patients with Neoadjuvant Immunotherapy. Cancer Science, 114, 4484-4498.
https://doi.org/10.1111/cas.15964
[33] Qi, W.X., Xiang, Y., Zhao, S. and Chen, J. (2021) Assessment of Systematic Inflammatory and Nutritional Indexes in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemotherapy and Atezolizumab. Cancer Immunology, Immunotherapy, 70, 3199-3206.
https://doi.org/10.1007/s00262-021-02926-3
[34] Zeng, Q., Li, J., Sun, N., Xue, Q., Gao, Y., Zhao, J., et al. (2021) Preoperative Systemic Immune-Inflammation Index Predicts Survival and Recurrence in Patients with Resected Primary Pulmonary Sarcomatoid Carcinoma. Translational Lung Cancer Research, 10, 18-31.
https://doi.org/10.21037/tlcr-20-960
[35] Li, H., Wang, G., Zhang, H., Song, X., Cao, J., Zhang, X., et al. (2019) Prognostic Role of the Systemic Immune-Inflammation Index in Brain Metastases from Lung Adenocarcinoma with Different EGFR Mutations. Genes & Immunity, 20, 455-461.
https://doi.org/10.1038/s41435-018-0050-z

为你推荐